Houston health tech company scores $2.2M grant to use AI to make organ transplants smarter, more successful

future of medicine

The NIH grant goes toward TransplantAI's work developing more precise models for heart and lung transplantation. Photo via Getty Images

The National Institute of Health has bestowed a Houston medtech company with a $2.2 million Fast-Track to Phase 2 award. InformAI will use the money for the product development and commercialization of its AI-enabled organ transplant informatics platform.

Last year, InformAI CEO Jim Havelka told InnovationMap, “A lot of organs are harvested and discarded.”

TransplantAI solves that problem, as well as organ scarcity and inefficiency in allocation of the precious resource.

How does it work? Machine learning and deep learning from a million donor transplants informs the AI, which determines who is the best recipient for each available organ using more than 500 clinical parameters. Organ transplant centers and organ procurement organizations (OPOs) will be able to use the product to make a decision on how to allocate each organ in real time. Ultimately, the tool will service 250 transplant centers and 56 OPOs around the United States.

The NIH grant goes toward developing more precise models for heart and lung transplantation (kidney and liver algorithms are further along in development thanks to a previous award from the National Science Foundation), as well as Phase 2 efforts to fully commercialize TransplantAI.

"There is an urgent need for improved and integrated predictive clinical insights in solid organ transplantation, such as for real-time assessment of waitlist mortality and the likelihood of successful post-transplantation outcomes," according to the grant’s lead clinical investigator, Abbas Rana, associate professor of surgery at Baylor College of Medicine.

“This information is essential for healthcare teams and patients to make informed decisions, particularly in complex cases where expanded criteria allocation decisions are being considered," Rana continues. "Currently, the separation of donor and recipient data into different systems requires clinical teams to conduct manual, parallel reviews for pairing assessments. Our team, along with those at other leading transplant centers nationwide, receives hundreds of organ-recipient match offers weekly.”

Organ transplantation is moving into the future, and Transplant AI is at the forefront.

From Your Site Articles
InformAI has three AI-based products geared at improving health care. Photo via Getty Images

Fresh off grant, Houston health tech company's AI aims to revolutionize diagnostics, care

data-driven

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston Nobel Prize nominee earns latest award for public health research

Prized Research

Houston vaccine scientist Dr. Peter Hotez can add one more prize to his shelf.

Hotez — dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, co-director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics — is no stranger to impressive laurels. In 2022, he was even nominated for a Nobel Peace Prize for his low-cost COVID vaccine.

His first big win of 2025 is this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project. The endeavor was born to help create a predictive disease atlas relating to climate disasters. Because the climate crisis has ushered in changes to the distribution of diseases, including dengue, chikungunya, Zika, Chagas disease, typhus and tick-borne relapsing fever, it’s important to predict outbreaks before they become a menace.

Rice University researchers are collaborating with Hotez and his team on a project that combines climate science and metagenomics to access 3,000 insect genomes. The goal is to aid health departments in controlling disease and informing policy.

The Hill Prize, which is being awarded to six innovators for the first time, thanks to a $10 million commitment from the philanthropic organization, is intended to back ideas that are high-risk and high-reward. Each of the projects was chosen for its potential real-life impact on some of Texas's — and the world’s — most challenging situations. Hotez’s prize is the first Hill Prize to be given in the realm of public health. The additional winners are:

  • Hill Prize in Medicine: Kenneth M. Hargreaves, D.D.S., Ph.D., The University of Texas Health Science Center at San Antonio
  • Hill Prize in Engineering: Joan Frances Brennecke, Ph.D. (NAE), The University of Texas at Austin
  • Hill Prize in Biological Sciences: David J. Mangelsdorf, Ph.D. (NAM, NAS), UT Southwestern Medical Center
  • Hill Prize in Physical Sciences: James Chelikowsky, Ph.D., The University of Texas at Austin
  • Hill Prize in Technology: Robert De Lorenzo, M.D., EmergenceMed, LLC
Read about other Houston-area researchers recognized by TAMEST here.

How Houston's cost of living compares to other major Texas cities in 2025

Calculating Costs

A new cost-of-living index yields a result that many Houstonians will find surprising: Houston is not the most expensive place to live in Texas. Dallas and Austin are costlier.

Numbeo’s cost-of-living index for 2025 shows Dallas ranks first in Texas and 24th in North America, landing at 65.8. The cost-of-living index compares the cost of living in New York City (which sits at 100) with the cost of living in another city. Austin is at 61.7, Houston at 60.6, and San Antonio at 58.8.

Houston ranks 40th overall in North America, out of 52 cities in the index.

Numbeo’s cost-of-living index takes into account the cost of items like groceries, restaurant meals, transportation, and utilities. The index excludes rent.

When rent is added to the cost-of-living index, Houston is still third among Texas cities. Dallas grabs the No. 21 spot in North America (57.1), one notch above Austin (56.6). Houston ranks 35th (51.4), and San Antonio ranks 42nd (34.6).

Rent index
While Dallas holds the top Texas spot on Numbeo’s overall cost-of-living index, Austin faces the highest rent prices. Numbeo's rent index for Austin sits at 50.1, putting it in 12th place among major cities in North America and highest in Texas, above the indexes for Dallas, Houston, and San Antonio. Houston lands at 27th.

The rent index in New York City, which tops the list, is 100. As Numbeo explains, the rent index estimates the cost of renting an apartment in a city compared with New York City. If the rent index is 50, for example, this suggests the average rent in that city is 50 percent below the average rent in New York City.

Around Texas, the rent index is:

  • 46.2 in Dallas
  • 39.8 in Houston
  • 34.6 in San Antonio

Restaurant index
In contrast to its showing on the rent and cost-of-living indexes, Houston outranks Dallas, Austin, and San Antonio on Numbeo’s restaurant index. This index compares the prices of meals and drinks at restaurants and bars to those in New York City.

Houston sits at No. 25 on the restaurant index, at 68.9. Dallas comes in at No. 32 (67.1), Austin at No. 34 (66.6), and San Antonio at No. 36 (65.2).

The National Restaurant Association reported in December that menu prices in the U.S. had risen 3.6 percent in the past 12 months, outpacing gains in grocery prices and the federal government’s overall Consumer Price Index. Fortunately for diners, that was the smallest 12-month increase in menu prices since August 2020, according to the association.

Toast, which provides a cloud-based restaurant management system, says the higher menu prices reflect higher food prices.

“Food prices have been increasing due to inflation, labor expenses, fuel costs, and supply chain disruptions, all of which impact restaurant profitability, Toast says. “While raising menu prices is one option to combat rising food costs, some restaurants have introduced service charges and simplified menus to avoid passing all costs onto customers.”

---

This story originally appeared on our sister site, CultureMap.com.

Houston startup taps strategic partner to produce novel 'biobased leather'

cleaner products

A Houston-based next-gen material startup has revealed a new strategic partnership.

Rheom Materials, formerly known as Bucha Bio, has announced a strategic partnership with thermoplastic extrusion and lamination company Bixby International, which is part of Rheom Material’s goal for commercial-scale production of its novel biobased material, Shorai.

Shorai is a biobased leather alternative that meets criteria for many companies wanting to incorporate sustainable materials. Shorai performs like traditional leather, but offers scalable production at a competitive price point. Extruded as a continuous sheet and having more than 92 percent biobased content, Shorai achieves an 80 percent reduction in carbon footprint compared to synthetic leather, according to Rheom.

Rheom, which is backed by Houston-based New Climate Ventures, will be allowing Bixby International to take a minority ownership stake in Rheom Materials as part of the deal.

“Partnering with Bixby International enables us to harness their extensive expertise in the extrusion industry and its entire supply chain, facilitating the successful scale-up of Shorai production,” Carolina Amin Ferril, CTO at Rheom Materials, says in a news release. “Their highly competitive and adaptable capabilities will allow us to offer more solutions and exceed our customers’ expectations.”

In late 2024, Rheom Materials started its first pilot-scale trial at the Bixby International facilities with the goal of producing Shorai for prototype samples.

"The scope of what we were doing — both on what raw materials we were using and what we were creating just kept expanding and growing," founder Zimri Hinshaw previously told InnovationMap.

Listen to Hinshaw on the Houston Innovators Podcast episode recorded in October.

View All Listings